beatandraise : Equity Research with AI and ChatGPT on SEC Edgar

beatandraise.com

2.2.0.7 false Consolidated Statements of Income (Unaudited) (USD $) 0110 - Statement - Consolidated Statements of Income (Unaudited) true false In Thousands, except Per Share data false false 1 USD false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 $ false 2 USD false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 $ false 3 USD false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 $ false 4 USD false false Shares Standard http://www.xbrl.org/2003/instance shares xbrli 0 USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 Pure Standard http://www.xbrl.org/2003/instance pure xbrli 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 $ 3 Revenues: 1 us-gaap_RevenuesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false 4 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 4 Product 2 us-gaap_SalesRevenueGoodsNet us-gaap true credit duration No definition available. false false false false false false false false false false false verboselabel false 1 true true false false 876850000 876850 false false false 2 true true false false 801689000 801689 false false false 3 true true false false 2560305000 2560305 false false false 4 true true false false 2326067000 2326067 false false false xbrli:monetaryItemType monetary Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false 5 Unconsolidated joint business 2 biib_UnconsolidatedJointBusiness biib false credit duration Revenues from unconsolidated joint business consists of our share of pretax co-promotion profits in the U.S.; reimbursement... false false false false false false false false false false false label false 1 false true false false 257981000 257981 false false false 2 false true false false 283919000 283919 false false false 3 false true false false 819281000 819281 false false false 4 false true false false 838307000 838307 false false false xbrli:monetaryItemType monetary Revenues from unconsolidated joint business consists of our share of pretax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pretax co-promotion profits in Canada. No authoritative reference available. false 6 Other 2 us-gaap_OtherSalesRevenueNet us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 40958000 40958 false false false 2 false true false false 34910000 34910 false false false 3 false true false false 117765000 117765 false false false 4 false true false false 85918000 85918 false false false xbrli:monetaryItemType monetary Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 true 7 Total revenues 2 us-gaap_Revenues us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 1175789000 1175789 false false false 2 false true false false 1120518000 1120518 false false false 3 false true false false 3497351000 3497351 false false false 4 false true false false 3250292000 3250292 false false false xbrli:monetaryItemType monetary Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 true 8 Costs and expenses: 1 us-gaap_CostsAndExpensesAbstract us-gaap true na duration No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false 4 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 9 Cost of sales, excluding amortization of acquired intangible assets 2 us-gaap_CostOfRevenue us-gaap true debit duration No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 95918000 95918 false false false 2 false true false false 93486000 93486 false false false 3 false true false false 299958000 299958 false false false 4 false true false false 282404000 282404 false false false xbrli:monetaryItemType monetary The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 false 10 Research and development 2 us-gaap_ResearchAndDevelopmentExpense us-gaap true debit duration No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 319054000 319054 false false false 2 false true false false 304055000 304055 false false false 3 false true false false 957759000 957759 false false false 4 false true false false 999986000 999986 false false false xbrli:monetaryItemType monetary The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 false 11 Selling, general and administrative 2 us-gaap_SellingGeneralAndAdministrativeExpense us-gaap true debit duration No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 244160000 244160 false false false 2 false true false false 226755000 226755 false false false 3 false true false false 755147000 755147 false false false 4 false true false false 669415000 669415 false false false xbrli:monetaryItemType monetary The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 4 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Chapter 4 -Paragraph 5A false 12 Collaboration profit sharing 2 biib_CollaborationProfitSharing biib false debit duration Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration... false false false false false false false false false false false verboselabel false 1 false true false false 63991000 63991 false false false 2 false true false false 60697000 60697 false false false 3 false true false false 190240000 190240 false false false 4 false true false false 152608000 152608 false false false xbrli:monetaryItemType monetary Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of Tysabri outside the U.S. increase, our collaboration profit sharing expense will increase. No authoritative reference available. false 13 Amortization of acquired intangible assets 2 us-gaap_AmortizationOfIntangibleAssets us-gaap true debit duration No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 53531000 53531 false false false 2 false true false false 51347000 51347 false false false 3 false true false false 155568000 155568 false false false 4 false true false false 233830000 233830 false false false xbrli:monetaryItemType monetary The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 45 -Subparagraph a(2) false 14 Acquired in-process research and development 2 biib_AcquiredInProcessResearchAndDevelopment biib false debit duration The amount of purchased research and development assets that are acquired in a business combination have no alternative... false false false false false false false false false false false totallabel false 1 false true false false 205000000 205000 false false false 2 false false false false 0 0 false false false 3 false true false false 244976000 244976 false false false 4 false false false false 0 0 false false false xbrli:monetaryItemType monetary The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. No authoritative reference available. true 15 Total costs and expenses 2 us-gaap_CostsAndExpenses us-gaap true debit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 981654000 981654 false false false 2 false true false false 736340000 736340 false false false 3 false true false false 2603648000 2603648 false false false 4 false true false false 2338243000 2338243 false false false xbrli:monetaryItemType monetary Total costs of sales and operating expenses for the period. No authoritative reference available. true 16 Income from operations 1 us-gaap_OperatingIncomeLoss us-gaap true credit duration No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 194135000 194135 false false false 2 false true false false 384178000 384178 false false false 3 false true false false 893703000 893703 false false false 4 false true false false 912049000 912049 false false false xbrli:monetaryItemType monetary The net result for the period of deducting operating expenses from operating revenues. No authoritative reference available. false 17 Other income (expense), net 1 us-gaap_OtherNonoperatingIncomeExpense us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false -6945000 -6945 false false false 2 false true false false 9360000 9360 false false false 3 false true false false -14318000 -14318 false false false 4 false true false false 30886000 30886 false false false xbrli:monetaryItemType monetary The net amount of other nonoperating income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 true 18 Income before income tax expense 1 us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments us-gaap true credit duration No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 187190000 187190 false false false 2 false true false false 393538000 393538 false false false 3 false true false false 879385000 879385 false false false 4 false true false false 942935000 942935 false false false xbrli:monetaryItemType monetary Sum of operating profit and nonoperating income (expense) before income (loss) from equity method investments, income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Subparagraph 1(i) -Article 4 false 19 Income tax expense 1 us-gaap_IncomeTaxExpenseBenefit us-gaap true debit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 75011000 75011 false false false 2 false true false false 113936000 113936 false false false 3 false true false false 252564000 252564 false false false 4 false true false false 271869000 271869 false false false xbrli:monetaryItemType monetary The sum of the current income tax expense (benefit) and the deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph a, b true 20 Net income 1 us-gaap_ProfitLoss us-gaap true credit duration No definition available. false false false false false false false false false false false verboselabel false 1 false true false false 112179000 112179 false false false 2 false true false false 279602000 279602 false false false 3 false true false false 626821000 626821 false false false 4 false true false false 671066000 671066 false false false xbrli:monetaryItemType monetary The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 5 -Subparagraph b Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) false 21 Net income (loss) attributable to noncontrolling interest, net of tax 1 us-gaap_NetIncomeLossAttributableToNoncontrollingInterest us-gaap true debit duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false -141936000 -141936 false false false 2 false true false false 1939000 1939 false false false 3 false true false false -138174000 -138174 false false false 4 false true false false 6571000 6571 false false false xbrli:monetaryItemType monetary The portion of net income (loss) attributable to the noncontrolling interest (if any) deducted in order to derive the portion attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(1) Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A1, A4, A5 true 22 Net income attributable to Biogen Idec Inc. 1 us-gaap_NetIncomeLoss us-gaap true credit duration No definition available. false false false false false false false false false false false totallabel false 1 true true false false 254115000 254115 false false false 2 true true false false 277663000 277663 false false false 3 true true false false 764995000 764995 false false false 4 true true false false 664495000 664495 false false false xbrli:monetaryItemType monetary The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 true 23 Net income per share: 1 us-gaap_EarningsPerShareAbstract us-gaap true na duration No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false 4 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 24 Basic earnings per share attributable to Biogen Idec Inc. 2 us-gaap_EarningsPerShareBasic us-gaap true na duration No definition available. false false false false false false false false false false false totallabel true 1 true true false false 1.06 1.06 false false false 2 true true false false 0.96 0.96 false false false 3 true true false false 2.98 2.98 false false false 4 true true false false 2.3 2.3 false false false us-types:perShareItemType decimal The amount of net income or loss for the period per each share of common stock outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 36, 37, 38 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 true 25 Diluted earnings per share attributable to Biogen Idec Inc. 2 us-gaap_EarningsPerShareDiluted us-gaap true na duration No definition available. false false false false false false false false false false false totallabel true 1 true true false false 1.05 1.05 false false false 2 true true false false 0.95 0.95 false false false 3 true true false false 2.95 2.95 false false false 4 true true false false 2.28 2.28 false false false us-types:perShareItemType decimal The amount of net income or loss for the period per each share of common stock and dilutive common stock equivalents outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 11, 12, 36 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 true 26 Weighted-average shares used in calculating: 1 us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract us-gaap true na duration No definition available. false false false false false true false false false false false verboselabel false 1 false false false false 0 0 false false false 2 false false false false 0 0 false false false 3 false false false false 0 0 false false false 4 false false false false 0 0 false false false xbrli:stringItemType string No definition available. false 27 Basic earnings per share attributable to Biogen Idec Inc. 2 us-gaap_WeightedAverageNumberOfSharesOutstandingBasic us-gaap true na duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 239864000 239864 false false false 2 false true false false 288917000 288917 false false false 3 false true false false 256586000 256586 false false false 4 false true false false 288416000 288416 false false false xbrli:sharesItemType shares Number of [basic] shares, after adjustment for contingently issuable shares and other shares not deemed outstanding, determined by relating the portion of time within a reporting period that common shares have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 171 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 true 28 Diluted earnings per share attributable to Biogen Idec Inc. 2 us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding us-gaap true na duration No definition available. false false false false false false false false false false false totallabel false 1 false true false false 242313000 242313 false false false 2 false true false false 291037000 291037 false false false 3 false true false false 258906000 258906 false false false 4 false true false false 290368000 290368 false false false xbrli:sharesItemType shares The average number of shares issued and outstanding that are used in calculating diluted EPS, determined based on the timing of issuance of shares in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 true 4 26 false Thousands Thousands NoRounding false true